<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ruiz-Irastorza G</submitter><funding>Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza</funding><pagination>e001562</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12107586</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus nephritis (LN) during an extended follow-up time up to 10 years.&lt;h4>Methods&lt;/h4>Patients with biopsy-proven class III, IV or V LN treated with LCN were compared with SOC. Patients in the LCN were treated with a CYC plus repeated methylprednisolone pulse-based regimen. The achievement of complete renal response (CRR) and the progression to chronic kidney disease (CKD) were the two main outcomes. Glucocorticoid (GC)-related toxicity, major infections and damage accrual were also analysed. A propensity score (PS)-adjusted multivariate analysis was used to overcome the confounding-by-indicatio</pubmed_abstract><journal>Lupus science &amp; medicine</journal><pubmed_title>Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts.</pubmed_title><pmcid>PMC12107586</pmcid><funding_grant_id>IT 1512-22</funding_grant_id><pubmed_authors>Ruiz-Irastorza G</pubmed_authors><pubmed_authors>Paredes Ruiz D</pubmed_authors><pubmed_authors>Osorio A</pubmed_authors><pubmed_authors>Marin-Garcia B</pubmed_authors><pubmed_authors>Duena-Bartolome L</pubmed_authors><pubmed_authors>Lazaro E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts.</name><description>&lt;h4>Objective&lt;/h4>To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus nephritis (LN) during an extended follow-up time up to 10 years.&lt;h4>Methods&lt;/h4>Patients with biopsy-proven class III, IV or V LN treated with LCN were compared with SOC. Patients in the LCN were treated with a CYC plus repeated methylprednisolone pulse-based regimen. The achievement of complete renal response (CRR) and the progression to chronic kidney disease (CKD) were the two main outcomes. Glucocorticoid (GC)-related toxicity, major infections and damage accrual were also analysed. A propensity score (PS)-adjusted multivariate analysis was used to overcome the confounding-by-indicatio</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2025-07-26T03:06:03.771Z</modification><creation>2025-07-26T03:06:03.771Z</creation></dates><accession>S-EPMC12107586</accession><cross_references><pubmed>40425263</pubmed><doi>10.1136/lupus-2025-001562</doi></cross_references></HashMap>